The state of Texas currently has 100 active clinical trials seeking participants for Diabetes research studies. These trials are conducted in various cities, including Houston, Dallas, San Antonio and Austin.
Feasibility and Effectiveness of Real-time, Remote Continuous Glucose Monitoring in Adolescents With Poorly Controlled Type 1 Diabetes
Recruiting
Adolescents with Type 1 Diabetes (age 13-18 years, T1D duration >6 months managed on insulin) and poor glycemic control will wear a blinded CGM to obtain baseline data. After assuring adherence to CGM wear, participants will receive a non-blinded CGM and will share their blood glucose levels with the study team. Clinical personnel will remotely monitor patients in real-time for 3 months and communicate regularly over secure text messaging with participants and their parents. Following active rem... Read More
Gender:
All
Ages:
Between 13 years and 18 years
Trial Updated:
09/15/2023
Locations: UT Southwestern Medical Center, Dallas, Texas
Conditions: Diabetes Mellitus, Type 1, Noncompliance, Patient
Effect of SGLT2i on Cardiovascular Biomarkers in Patients With Type 2 Diabetes and CKD Stage 3b-4
Recruiting
This is a prospective, observational study to assess the effect of SGLT2 inhibitors on surrogate markers of kidney and cardiovascular health in patients with stage 3b and 4 chronic kidney disease (CKD). This study includes three clinic in person visits and weekly telephone visits for 12 weeks. Recruit 28 patients with CKD stages 3b-4 and follow up for 12 weeks Determine the effect of interventions on the primary outcome variable serum klotho measured by immunoprecipitation-immunoblot
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
08/29/2023
Locations: UT Southwestern Medical Center, Dallas, Texas
Conditions: Kidney Disease, Chronic, Diabetes
Healthy Communities Through CHW Initiatives
Recruiting
Latino(a)s suffer from poor social determinants of health (SODH) conditions more than non-minority populations, and being a minority is risk factor alone for diabetes. In the proposed study, investigators will assist church members in becoming Community Health Workers (CHWs), train them in diabetes, and use an online platform (Salesforce) to track the ability to address healthcare access and quality barriers.
Gender:
All
Ages:
18 years and above
Trial Updated:
08/25/2023
Locations: University of Texas Medical Branch at Galveston, Galveston, Texas
Conditions: Diabetes Mellitus, Type 2
Resilience-Based Diabetes Self-Management Education (RB-DSME) for African Americans
Recruiting
African Americans are twice as likely to have type 2 diabetes as non-Hispanic Whites and are less likely to engage in effective diabetes self-management. There is a critical need for intensive lifestyle interventions that address the distress inherent in having the disease and the unique stressors faced by African Americans that may worsen diabetes-related health outcomes. Our program, Resilience-Based Diabetes Self-Management Education and Support, integrates resilience resources with diabetes... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
08/22/2023
Locations: University of Texas at Austin, Austin, Texas
Conditions: Type 2 Diabetes
Quantifying Hepatic Mitochondrial Fluxes in Humans
Recruiting
In this study the investigators will quantitate hepatic mitochondrial fluxes in T2D patients with NAFL and NASH before and after 16-weeks treatment with the insulin sensitizer pioglitazone
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
08/21/2023
Locations: Texas Diabetes Institute - University Health System, San Antonio, Texas +1 locations
Conditions: Non-Alcoholic Fatty Liver Disease, Type 2 Diabetes, Mitochondrial Metabolism Disorders
XW014 in Healthy Subjects and Patients With Type 2 Diabetes Mellitus (T2DM)
Recruiting
This is a Phase 1, randomized, double-blind, placebo-controlled, first-in-human (FIH) study to evaluate the safety, tolerability, food effect (FE), pharmacokinetics (PK), and pharmacodynamics (PD) of orally administered XW014 in healthy participants and patients with T2DM. This study will consist of 3 parts: a Single Ascending Dose (SAD) part in healthy subjects (Part A), and Multiple Ascending Dose (MAD) parts in healthy subjects with elevated BMI (Part B) and patients with T2DM (Part C).
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
08/14/2023
Locations: ICON - Early Development Services, San Antonio, Texas
Conditions: Type 2 Diabetes Mellitus
Evaluating Telementoring for CHW-centered Diabetes Initiatives
Recruiting
Diabetes care is complex and requires a multidimensional approach, but interventional programs are difficult to initiate in low-income and minority populations. In the proposed study, investigators will mentor local clinics via telehealth to initiate our diabetes program, TIME (Telehealth-supported, Integrated CHWs, Medication-access, group visit Education), into their clinics. Mentoring local clinics to initiate TIME is a promising strategy to enhance sustainable diabetes care and reduce dispar... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
08/04/2023
Locations: Baylor College of Medicine, Houston, Texas
Conditions: Diabetes Mellitus, Type 2
Pre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT)
Recruiting
HYPOTHESIS: Impaired glucose tolerance (IGT) and impaired fasting glucose (IFG) have distinct pathophysiologic etiologies. Therefore, therapeutic interventions designed to correct the specific underlying pathogenic abnormalities in IGT and IFG will be required to optimally prevent the progressive beta cell failure and development of overt type 2 diabetes.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
08/02/2023
Locations: The University of Texas Health Science Center at San Antonio, San Antonio, Texas
Conditions: Diabetes Mellitus, Type 2, Impaired Glucose Tolerance (IGT), Impaired Fasting Glucose (IFG)
Fit 24 Technology Intervention YOUTH
Recruiting
The purpose of this study is to examine the effects of a goal-setting intervention that utilizes a Fitbit device and text messaging to improve physical activity and sleep in Hispanic adolescents with obesity.
Gender:
All
Ages:
Between 14 years and 16 years
Trial Updated:
07/31/2023
Locations: Baylor College of Medicine, Houston, Texas
Conditions: Diabetes Mellitus, Type 2
Pioglitazone on Heart Failure in Type-2 Diabetes Mellitus Participants
Recruiting
Our goal of the study is to learn the effects of the diabetes medication named Pioglitazone, in type-2 diabetic obese participants with Heart failure. The main question it aims to answer are: To demonstrate that impaired mitochondrial function leading to reduced ATP generation plays a key pathophysiologic role in the development of heart failure with preserved ejection fraction (HFpEF) in obese type 2 diabetic (T2D) individuals. To demonstrate that pioglitazone, improves diastolic (as well as s... Read More
Gender:
All
Ages:
Between 30 years and 70 years
Trial Updated:
07/13/2023
Locations: Texas Diabetes Institute/UH, San Antonio, Texas
Conditions: Type 2 Diabetes Mellitus in Obese, Heart Failure With Preserved Ejection Fraction
Collection of Blood From Healthy Patients, Patients With Benign Disease and Patients With Cancer
Recruiting
To acquire blood samples from subjects for various purposes, including: i) determining the sensitivity and specificity of select DNA methylation markers for the detection of various types of cancer, ii) identifying benign conditions that may induce false positive or false negative results, and iii) defining the effects of potential interfering substances, such as chemotherapy drugs.
Gender:
All
Ages:
18 years and above
Trial Updated:
07/10/2023
Locations: Liver Center of Texas, Dallas, Texas +1 locations
Conditions: Cancer, Liver Cirrhosis, Chronic Hepatitis, Hepatitis B, Hepatitis C, Diabetes, COPD
BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes
Recruiting
An observational study of electronic patient data to compare diabetes medications and to determine which ones offer the best balance of risks and benefits.
Gender:
All
Ages:
30 years and above
Trial Updated:
06/16/2023
Locations: Baylor Scott & White, Dallas, Texas
Conditions: Diabetes Mellitus, Type 2